Digital Health Leaders Meet at HIMSS24 Europe to Deliver Solutions to Tomorrow’s Healthcare Challenges
To address Europe’s most pressing healthcare challenges, Europe's longest-running, most influential digital health conference returns in 2024, bringing together innovators to shape tomorrow’s healthcare.
The HIMSS24 European Health Conference & Exhibition will occur from 29-31 May at the Centro Congressi Roma La Nuvola in Rome, Italy. The conference will be the epicenter for pan-European collaborations and innovation, featuring thought leaders and healthcare professionals working together to create the best technology solutions across the digital health landscape.
HIMSS24 Europe will feature programming focused on major global health challenges. Experts will lead discussions on how Europe uses data analytics, artificial intelligence, cybersecurity, and other cutting-edge technologies to address universal issues like health equity, patient privacy, access to care, workforce burnout, staffing shortages, and climate change.
Registration is open for HIMSS24 Europe, and interested journalists can contact HIMSS to receive complimentary press credentials. The conference will attract thousands of industry experts worldwide, including CIOs and CTOs, AI experts, cybersecurity leaders, data scientists, healthcare practitioners, and public health policy leaders.
“We’ve built an innovative programme that offers the tools and insights healthcare professionals need to transform systems and improve outcomes,” said Ronan O’Connor, Managing Director, EMEA and Vice President at HIMSS. “This year, we are proud to bring executives, policymakers, and healthcare professionals of all kinds together in Italy, which is a leader in digital health innovation.”
The program lineup includes a deep dive into Europe’s current regulatory landscape, including the AI Act, the European Health Data Space (EHDS), and the European Recovery and Resilience Fund. This year’s keynote speakers will lend their expertise to enrich discussions on pressing healthcare issues.
- Marco Marsella, director, Digital, EU4Health and Health Systems Modernisation and DG SANTE, European Commission.
- Hela Ghariani, co-head of the Digital Health Delegation, Ministry of Social Affairs and Health, France and co-chair of the EU eHealth Network.
- John Riggi, FBI veteran and national advisor for cybersecurity and risk at the American Hospital Association
- Sharon Allen, co-founder and chief executive officer of World Telehealth Initiative, a remote philanthropic model that allows physicians to provide sustainable medical expertise via telehealth.
- Dr. Waheed Arian, founder of Arian Wellbeing.
Emerging topics such as the ethical use of AI in healthcare and finding the balance between effective data sharing and protecting patient privacy will be top of mind for presenters and attendees.
The conference will showcase emerging healthcare solutions through Startup Pitchfest, offering a platform for innovative startups to address entrenched challenges faced by health systems and providers.
The conference programming is supported by a Programme Committee comprising 17 highly reputable and well-respected healthcare professionals from across Europe.
Networking opportunities and interactive experiences will also be at the forefront of HIMSS24 Europe, where attendees can connect with representatives from more than 70 countries representing the global health ecosystem.
Click here to learn more about HIMSS24 Europe.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240424984367/en/
Contact information
Albe Zakes, HIMSS Public Relations Director
albe.zakes@himss.org | +1.267.221.4800
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press Release
Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 100 points. TIME and Statista analyzed 3,000 major companies from 150 countries, focusing exclusively on those with trans
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press Release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press Release
ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors (corner cube prisms) designed to reflect laser beams directly back to their source, regardless of the an
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press Release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom